Ex-Vivo and In-Vivo Assessment of Cyclamen europaeum Extract After Nasal Administration
Metadata
Show full item recordAuthor
Fernández-Campos, Francisco; Clares Naveros, Beatriz; Rodriguez-Lagunas, María José; Jauregui, Olga; Casals, Isidre; Calpena-Campmany, AnaEditorial
MDPI
Materia
Cyclamen europaeum Nasal dosage form Nasal drug delivery Permeability Rhinosinusitis
Date
2019-08-21Referencia bibliográfica
Fernández-Campos, F.; Clares, B.; Rodríguez-Lagunas, M.J.; Jauregui, O.; Casals, I.; Calpena, A.C. Ex-Vivo and In-Vivo Assessment of Cyclamen europaeum Extract After Nasal Administration. Pharmaceutics 2019, 11, 426. [doi:10.3390/pharmaceutics11090426]
Abstract
Rhinosinusitis is a prevalent disorder with a severe impact on the health-related quality of life. Saponins of Cyclamen europaeum exert a clinically proven curative effect on rhinosinusitis symptoms when instilled into the nasal cavity, however, more extensive preclinical assessment is required to better characterize the efficacy of this botanical extract. This work evaluates the potential use of a natural freeze-dried extract of C. europaeum given as topical nasal administration. Permeation experiment on porcine nasal mucosa was performed with Franz diffusion cells. Experiments in rabbits were performed to test for any toxicological, hematological, biochemical or histological evidence of systemic action. No theoretical levels of saponins were found in the receptor chamber of Franz diffusion cells. Hematological data did not show significant differences between control and experimental animals (p > 0.05). Histological studies also showed that enhanced secretory activity in response to intranasal administration was not accompanied by any visible signs of injury. An examination of the brain, lungs, liver, kidneys, spleen, and gastrointestinal organs did not reveal any abnormality. The absence of mucosal permeation of saponins and negligible probability of C. europaeum saponins absorption in the course of a therapeutic application was demonstrated.